Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-α or 5,6 MeXAA

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Watts, M E ^a   Arnold, S ^a   Chaplin, D J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Human umbilical vein endothelial cell; Hypoxia; MDA MB 231 cell; Tumour microenvironment

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; TUMOR NECROSIS FACTOR ALPHA; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; ANTINEOPLASTIC AGENT; FLAVONOID; MITOFLAXONE; XANTHENE DERIVATIVE; XANTHONE DERIVATIVE;

BLOOD CLOTTING; BLOOD CLOTTING TIME; BREAST ADENOCARCINOMA; CELL MEMBRANE PERMEABILITY; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; OXYGEN TENSION; PRIORITY JOURNAL; UMBILICAL VEIN; ARTICLE; CAPILLARY PERMEABILITY; CELL CULTURE; CYTOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; CAPILLARY PERMEABILITY; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0029948105     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. BIBBY MC, DOUBLE JA, LOADMAN PM AND DUKE CV. (1989). Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy J. Natl Cancer Inst., 81, 216-220.
2. BORENFREUND E, BABICH H AND MARTIN-ALGUACIL N. (1990). Rapid chemosensitivity assay with human normal and tumor cells in vitro. In Vitro Cell Dev. Biol., 26, 1030-1034.
3. BURKE-GAFFNEY A AND KEENAN AK. (1993). Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 α/β tumor necrosis factor-α and interferon-γ. Immunopharmacology, 25, 1-9.
4. CARSWELL EA, OLD LJ, KASSEL RL, GREEN S, FIORE N AND WILLIAMSON B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA, 72, 3666-3670.
5. CHABOT GG, BRANELLEC D, SASSI A, ARMAND J-P, GOUYETTE A AND CHOUAIB S. (1993). Tumour necrosis factor-α plasma levels after flavone acetic acid administration in man and mouse. Eur. J. Cancer, 29A 729-733.
6. CHAPMAN JD, STURROCK J, BOAG JW AND CROOKALL JO. (1970). Factors affecting the oxygen tension around cells growing in plastic Petri dishes. Int. J. Radiat. Biol., 17, 305-328.
7. CHING L-M, JOSEPH WR, CROSIER KE AND BAGULEY BC. (1994). Induction of tumour necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5, 6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res., 54, 870-872.
8. CLAUS M, GERLACH M, GERLACH H, BRETT J, WANG F, FAMILLETTI PC, PAN Y-CE, OLANDER JV, CONNOLLY DT AND STERN D. (1990). Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J. Exp. Med., 172, 1535-1545.
9. COLLINS PD, CONNOLLY DT AND WILLIAMS TJ. (1993). Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br. J. Pharmacol., 109 195-199.
10. FREITAS I AND BARONZIO GF. (1991). Tumor hypoxia reoxygenation and oxygenation strategies: possible role in photodynamic therapy. J. Photochem. Photobiol. B: Biol., 11, 3-30.
11. FUTAMI H, EADER LA, KOMSCHLIES KL, BULL R, GRUYS ME, ORTALDO JR, YOUNG HA AND WILTROUT RH. (1991). Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes. Cancer Res., 51, 6596-6602.
12. GERTLER JP, WEIBE DA, OCASIO VH AND ABBOTT WM. (1991). Hypoxia induces procoagulant activity in cultured human venous endothelium. J. Vasc. Surg., 13, 428-433.
13. HARANAKA K, SATOMI N AND SAKURAI A. (1984). Antitumour activity of murine tumour necrosis factor (TNF). against transplanted murine tumours and heterotransplanted human tumours in nude mice. Int. J. Cancer, 34, 263-267.
14. HILL S, WILLIAMS KB AND DENEKAMP J. (1989). Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour action. Eur. J. Cancer Clin. Oncol., 25, 1419-1424.
15. HILL SA, SAMPSON LE AND CHAPLIN DJ. (1995). Antivascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer. 63, 119-123.
16. HOLMLUND JT, KOPP WC, WILTROUT RH, LONGO DL, URBA WJ, JANIK JE, SZNOL M, CONLON KC, FENTON RG, HORNUNG R, MADARA K, SHIELDS MA, SMITH II JW, SHARFMAN W, STEIS RG, EWEL C, MALSPEIS L AND CREEKMORE SP. (1995). A Phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2. J. Natl Cancer Inst., 87, 134-136.
17. JAFFE EA, NACHMAN RL, BECKER CG AND MINICK CR. (1973). Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J. Clin. Invest., 52, 2745-2756.
18. KERR DJ, KAYE SB, CASSIDY J, BRADLEY C, RANKIN EM, ADAMS L, SETANOIANS A, YOUNG T, FORREST G, SOUKOP M AND CLAVEL M. (1987). Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res., 47, 6776-6781.
19. LAWS AL, MATTHEW AM, DOUBLE JA AND BIBBY MC. (1995). Preclinical in vitro and in vivo activity of 5, 6-dimethylxanthenone-4-acetic acid. Br. J. Cancer, 71, 1204-1209.
20. MACE KF, HORNUNG RL, WILTROUT RH AND YOUNG HA. (1990). Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res., 50, 1742-1747.
21. MUELLER-KLIESER W, VAUPEL P, MANZ R AND SCHMIDSEDER R. (1981). Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int. J. Radiat. Oncol. Biol. Phys., 7, 1397-1404.
22. MURRAY JC, SMITH KA AND THURSTON G. (1989). Flavone acetic acid induces a coagulopathy in mice. Br. J. Cancer, 60, 729-733.
23. MURRAY JC, SMITH KA AND STERN DM. (1991). Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumour necrosis factor. Eur. J. Cancer, 27,. 765-770.
24. NAWROTH P, HANDLEY D, MATSUEDA G, DE WAAL R, GERLACH H, BLOHM D AND STERN D. (1988). Tumor necrosis factor/ cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med., 168, 637-647.
25. OGAWA S, SHREENIWAS R, BRETT J, CLAUSS M, FURIE M AND STERN DM. (1990). The effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulant function. Br. J. Haematol., 75, 517-524.
26. OLVER IN, WEBSTER LK BISHOP JF AND STOKES KH. (1992). A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid. Cancer Chemother. Pharmacol., 29, 354-360.
27. PARK Y-MK, ANDERSON RL, SPITZ DR AND HAHN GM. (1992). Hypoxia and resistance to hydrogen peroxide confer resistance to tumor necrosis factor in murine L929 cells. Radiat Res., 131, 162-168.
28. REWCASTLE GW, ATWELL GJ, ZHUANG L, BAGULEY BC AND DENNY WA. (1991). Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem., 34, 217-222.
29. RICKLES FR AND EDWARDS RL. (1983). Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood, 6, 14-31.
30. RICKLES FR, LEVINE M AND EDWARDS RL. (1992). Hemostatic alterations in cancer patients. Cancer Metast. Rev., 11, 237-248.
31. SAKS S AND ROSENBLUM M. (1991). Recombinant human TNF-α: Preclinical studies and results from early clinical trials In Tumour Necrosis Factors: Structure Function and Mechanism of Action, Agrawal BB and Vilcek J. (eds). pp. 567-587. Marcel Dekker: New York.
32. SAMPSON LE AND CHAPLIN DJ. (1994). The influence of microenvironment on the cytotoxicity of TNFα in vitro. Int. J. Radiat. Oncol. Biol. Phys., 29, 467-471.
33. SENGER DR, PERRUZZI CA, FEDER J AND DVORAK HF. (1986). A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res., 46, 5629-5632.
34. SPRIGGS DR, SHERMAN ML, MICHIE H, ARTHUR KA, IMAMURA K, WILMORE D, FREI III E AND KUFE DW. (1988). Recombinant human tumour necrosis factor administered as a 24-hour intravenous infusion A phase I and pharmacologic study. J. Natl Cancer Inst., 80, 1039-1044.
35. SUN NCJ, MCAFFEE WM, HUM GJ AND WEINER JM. (1979). Hemostatic abnormalities in malignancy a prospective study of one hundred eight patients. Am. J. Clin. Pathol., 71, 10-16.
36. THOMLINSON RH AND GRAY LH. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 9, 539-549.
37. WATTS ME AND WOODCOCK M.(1992). Flavone acetic acid induced changes in human endothelial permeability: potentiation by tumour-conditioned medium. Eur. J. Cancer, 28A 1628-1632.
38. WORKMAN P AND STRATFORD IJ. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast. Rev., 12, 73-82.